Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial

doi:10.3748/wjg.v30.i30.3564

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 30

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1760)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

128

HTML

982

Figures (1-4)

143

Tables (1-4)

137

Sum=1390

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

266

Sum=303

Aug 14, 2024 (publication date) through Feb 7, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Aug 14, 2024; 30(30): 3564-3573
Published online Aug 14, 2024. doi: 10.3748/wjg.v30.i30.3564

Full Size Figure Download Figure

Figure 4 Kaplan-Meier curves for patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. A: Progression-free survival; B: Overall survival. PFS: Progression-free survival; OS: Overall survival; GBC: Gallbladder cancer; ICC: Intrahepatic cholangiocarcinoma; ECC: Extrahepatic cholangiocarcinoma.

Citation: Xu LX, Yuan JJ, Xue R, Zhou J. Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial. World J Gastroenterol 2024; 30(30): 3564-3573
URL: https://www.wjgnet.com/1007-9327/full/v30/i30/3564.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i30.3564